134 related articles for article (PubMed ID: 2014946)
1. Prognostic value of serum beta-2 microglobulin in low-grade lymphoma.
Litam P; Swan F; Cabanillas F; Tucker SL; McLaughlin P; Hagemeister FB; Rodriguez MA; Velasquez WS
Ann Intern Med; 1991 May; 114(10):855-60. PubMed ID: 2014946
[TBL] [Abstract][Full Text] [Related]
2. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease.
Chronowski GM; Wilder RB; Tucker SL; Ha CS; Sarris AH; Hagemeister FB; Barista I; Hess MA; Cabanillas F; Cox JD
Cancer; 2002 Dec; 95(12):2534-8. PubMed ID: 12467067
[TBL] [Abstract][Full Text] [Related]
3. Serum beta 2-microglobulin in malignant lymphoma.
Hagberg H; Killander A; Simonsson B
Cancer; 1983 Jun; 51(12):2220-5. PubMed ID: 6189572
[TBL] [Abstract][Full Text] [Related]
4. Beta-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas.
Johnson PW; Whelan J; Longhurst S; Stepniewska K; Matthews J; Amess J; Norton A; Rohatiner AZ; Lister TA
Br J Cancer; 1993 Apr; 67(4):792-7. PubMed ID: 8471438
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lymphocytic leukemia.
Kantarjian HM; Smith T; Estey E; Polyzos A; O'Brien S; Pierce S; Beran M; Feldman E; Keating MJ
Am J Med; 1992 Dec; 93(6):599-604. PubMed ID: 1466355
[TBL] [Abstract][Full Text] [Related]
6. Prognostic role of serum beta 2-microglobulin in Hodgkin's disease.
Dimopoulos MA; Cabanillas F; Lee JJ; Swan F; Fuller L; Allen PK; Hagemeister FB
J Clin Oncol; 1993 Jun; 11(6):1108-11. PubMed ID: 8501496
[TBL] [Abstract][Full Text] [Related]
7. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels.
Swan F; Velasquez WS; Tucker S; Redman JR; Rodriguez MA; McLaughlin P; Hagemeister FB; Cabanillas F
J Clin Oncol; 1989 Oct; 7(10):1518-27. PubMed ID: 2674337
[TBL] [Abstract][Full Text] [Related]
8. The Merlini, Waldenström, Jayakar staging system revisited.
Merlini G; Gobbi PG; Ascari E
Eur J Haematol Suppl; 1989; 51():105-10. PubMed ID: 2697581
[TBL] [Abstract][Full Text] [Related]
9. Serum beta 2-microglobulin in patients with adult T-cell leukemia.
Tsuda H; Ishii T; Sawada T; Takatsuki K
Acta Haematol; 1991; 86(1):31-5. PubMed ID: 1950359
[TBL] [Abstract][Full Text] [Related]
10. Beta-2-microglobulin is superior to N-acetyl-beta-glucosaminidase in predicting prognosis in idiopathic membranous nephropathy.
Hofstra JM; Deegens JK; Willems HL; Wetzels JF
Nephrol Dial Transplant; 2008 Aug; 23(8):2546-51. PubMed ID: 18308774
[TBL] [Abstract][Full Text] [Related]
11. Serum tumor markers in non-Hodgkin's lymphomas and chronic lymphocytic leukemia.
Pavlidis AN; Kalef-Ezra J; Bourantas LC; Lambrou A; Mavridis A
Int J Biol Markers; 1993; 8(1):14-20. PubMed ID: 8496627
[TBL] [Abstract][Full Text] [Related]
12. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma.
Hallek M; Wanders L; Ostwald M; Busch R; Senekowitsch R; Stern S; Schick HD; Kuhn-Hallek I; Emmerich B
Leuk Lymphoma; 1996 Aug; 22(5-6):439-47. PubMed ID: 8882957
[TBL] [Abstract][Full Text] [Related]
13. Serum beta 2-microglobulin in patients with non-Hodgkin's lymphoma.
Anderson H; Scarffe JH; Swindell R; Crowther D
Eur J Cancer Clin Oncol; 1983 Mar; 19(3):327-31. PubMed ID: 6190656
[TBL] [Abstract][Full Text] [Related]
14. [A analysis of the outcome and prognostic factors in 415 patients with Hodgkin lymphoma].
Tao Y; Kang S; Zhou L; Shi Y; Li Y; Sun Y
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):466-71. PubMed ID: 26463153
[TBL] [Abstract][Full Text] [Related]
15. Correlation and prognostic value of serum soluble ICAM-1, beta-2 microglobulin, and IL-2alphaR levels in non-Hodgkin's lymphoma.
Pérez-Encinas M; Quintas A; Bendaña A; Rabuñal MJ; Bello JL
Leuk Lymphoma; 1999 May; 33(5-6):551-8. PubMed ID: 10342582
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma.
Cowan RA; Jones M; Harris M; Steward WP; Radford JA; Wagstaff J; Deakin DP; Crowther D
Br J Cancer; 1989 Feb; 59(2):276-82. PubMed ID: 2930692
[TBL] [Abstract][Full Text] [Related]
17. Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma.
Greipp PR; Katzmann JA; O'Fallon WM; Kyle RA
Blood; 1988 Jul; 72(1):219-23. PubMed ID: 3291982
[TBL] [Abstract][Full Text] [Related]
18. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
19. Treatment results of chemoradiation therapy for localized aggressive lymphomas: A retrospective 20-year study.
Yamashita H; Izutsu K; Nakamura N; Shiraishi K; Chiba S; Kurokawa M; Tago M; Igaki H; Ohtomo K; Nakagawa K
Ann Hematol; 2006 Aug; 85(8):523-9. PubMed ID: 16691398
[TBL] [Abstract][Full Text] [Related]
20. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma.
Greipp PR; Lust JA; O'Fallon WM; Katzmann JA; Witzig TE; Kyle RA
Blood; 1993 Jun; 81(12):3382-7. PubMed ID: 8507875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]